Content Type: Article

  • SEC Adopts Final Rule to Prohibit Conflicts of Interest in Certain Securitizations

    SEC Adopts Final Rule to Prohibit Conflicts of Interest in Certain Securitizations

    ARTICLE / CLIENT ALERT

    SEC Adopts Final Rule to Prohibit Conflicts of Interest in Certain Securitizations

    December 15, 2023

    Read time: 23 min

    Key takeaways
    Overview

    Introduction

    On Nov. 27, 2023, the Securities and Exchange Commission (“SEC”) adopted Securities Act Rule 192 (“Rule”)[1] to implement Section 27B of the Securities Act of 1933 (“Securities Act”), a provision added by Section 621 of the Dodd-Frank Wall Street Reform and Consumer Protection Act. The Rule is intended to prevent the sale of asset-backed securities (“ABS”) that are affected by material conflicts of interest, and to that end prohibits a securitization participant, for a specified period of time, from engaging, directly or indirectly, in any transaction that would involve or result in any material conflict of interest between the securitization participant and an investor in the relevant ABS (“conflicted transaction”).[2]

    The original proposed rule to restrict material conflicts of interest in ABS sales (by implementing Section 27B of the Securities Act) was released more than a dozen years ago when the SEC proposed Rule 127B[3]. The initial proposal faced significant criticism from the industry, leading to a lack of further action by the SEC at that time. An update to the original proposed rule was released on Jan. 25, 2023 (“Proposed Rule”)[4], and that Proposed Rule again elicited many comments from industry participants.

    Overview

    The final Rule was adopted with various amendments and updates to the Proposed Rule based upon the SEC’s updated analysis and market feedback. Under the Rule, a securitization participant is prohibited from engaging in conflicted transactions.[5] This prohibition commences on the date such person has reached an agreement to become a securitization participant with respect to the ABS, and ends on the date which is one year after the first closing of the sale of the ABS.[6] It should be noted that the final Rule does not require the agreement to be in writing, and therefore the commencement date, and the Rule’s prohibitions, may begin prior to any written agreement.

    Conflicted Transactions

    A conflicted transaction is defined as any one of three delineated activities: (i) a short sale of the relevant ABS, (ii) the purchase of a credit default swap or other credit derivative pursuant to which the securitization participant would be entitled to receive payments upon the occurrence of specified credit events in respect of the ABS and (iii) the purchase or sale of any financial instrument (other than the ABS) that is substantially the economic equivalent of a either (i) or (ii) above (other than transactions that only hedge the general interest rate or currency exchange risk).[7] The catch-all provision in clause (iii) (conflicted transactions based on “substantially the economic equivalent of” transactions) is a substantial clarification and narrowing of the range of possible covered transactions originally included in the Proposed Rule.

    The SEC’s release accompanying the Rule states that in cases where the asset pool comprises a large number of different and distinct obligations, engaging in a “short transaction with respect to a single asset or some non-sizeable portion of the assets in that pool” would generally not result in a short position which is “substantially the economic equivalent” of a short of the ABS itself (or a credit default swap or other credit derivative where the participant would be entitled to receive payment on specified credit events on the ABS).[8] However, if the assets of such a transaction constitute a “sizeable portion”[9] of the overall asset pool supporting or referenced by the relevant ABS, the transaction may be a conflicted transaction based on the specific facts and circumstances. If the transaction is deemed a conflicted transaction based on the foregoing, it could still be eligible for the risk-mitigating hedging activities exception discussed below.

    The definition of a “conflicted transaction” also contains a materiality standard, which requires that there be “a substantial likelihood that a reasonable investor would consider the relevant transaction important to the investor’s investment decision, including a decision whether to retain the asset-backed security.”[10]

    Exceptions

    The Rule provides exceptions for risk-mitigating hedging activities, liquidity commitments and bona fide market-making activities of a securitization participant, permitting market participants to engage in such market activities subject to satisfaction of specified conditions.[11] These have remained largely unchanged from the language of the Proposed Rule.

    Exception for Risk-Mitigating Hedging Activities

    “Risk-mitigating hedging activities” are defined as transactions entered into and related to individual or aggregated positions, contracts or other holdings of the securitization participant, including those arising out of its securitization activities such as the origination or acquisition of assets that it securitizes[12]. Such risk-mitigating hedging activities are only permitted if certain conditions are satisfied, including: (i) the risk-mitigating hedging activity is designed to reduce or mitigate specific, identifiable risks of the identified positions, contracts, or other holdings of the securitization participant; (ii) the risk-mitigating hedging activity is subject to ongoing calibration by the securitization participant to ensure it continues to satisfy the defined permitted uses; and (iii) the securitization participant establishes, implements, maintains and enforces an internal compliance program reasonably designed to ensure compliance with the defined permitted uses.[13]

    Exception for Liquidity Commitments

    Purchases or sales of the ABS made pursuant to, and consistent with, commitments of the securitization participant to provide liquidity for the ABS are not prohibited by the final Rule. Such activities may include commitments to promote full and timely interest payments to ABS investors or to provide financing to accommodate differences in the payment dates between the ABS and the underlying assets.[14] An extension of credit by a securitization participant that functions to support the performance of the securitization rather than to benefit from its adverse performance will not be a conflicted transaction under the final Rule.[15]

    Exception for Bona Fide Market-Making Activities

    Certain bona fide market-making activities, including market-making related to hedging, in connection with the ABS, the assets underlying the ABS or financial instruments that reference such ABS or the underlying assets, are in each case allowed (where the initial distribution of ABS is not considered bona fide market-making). Bona fide market-making is permitted if: (i) the securitization participant is ready to purchase and sell bona fide market-making financial instruments in commercially reasonable amounts and throughout market cycles on a basis appropriate for the liquidity, maturity and depth of the market; (ii) the market-making activities are designed not to exceed the reasonably expected near term demands of clients, customers or counterparties; (iii) the compensation arrangements do not reward or incentivize conflicted transactions; (iv) the securitization participant is registered, if required, to engage in such activities; and (v) the securitization participant establishes, implements, maintains and enforces an internal compliance program reasonably designed to ensure compliance with the permitted bona fide market-making activity.[16]

    Anti-Evasion

    The Proposed Rule contained an “Anti-circumvention”[17] clause which has been amended to now be an “Anti-evasion” clause in the final Rule.[18] This narrowing has resulted in such “evasion” requiring an actual “scheme” to evade, as opposed to any transaction itself being previously able to trigger an “anti-circumvention” violation.

    Securitization Participant

    The definition of “securitization participant”, which includes (i) an underwriter, placement agent, initial purchaser or sponsor of the ABS and (ii) any affiliate or subsidiary thereof, was also narrowed to clarify that any such affiliate or subsidiary must also (A) act in coordination with the underwriter, placement agent, initial purchaser or sponsor or (B) have access to or receive information about the ABS or the underlying asset pool prior to the first closing of sale of the relevant ABS.[19] This narrowing provides some relief to large institutions which would have otherwise had subsidiaries or affiliates, even those not involved with the ABS, at risk of being captured by the definition of securitization participant under the Proposed Rule; however, these institutions will need to devise appropriate compliance rules and mechanisms to accommodate this and to prevent the coordination or sharing of information tailored to their respective organizations.[20] We discuss the Rule’s applicability to affiliates and subsidiaries in further detail below.

    Underwriter, Placement Agent and Initial Purchaser

    The Rule defines “placement agent” and “underwriter” as a person who has agreed with an issuer or selling security holder to: (i) purchase securities from the issuer or selling security holder for distribution; (ii) engage in a distribution for or on behalf of such issuer or selling security holder; or (iii) manage or supervise a distribution for or on behalf of such issuer or selling security holder.[21]

    “Distribution” as used in the definitions for “underwriter” and “placement agent” means: “an offering of securities, whether or not subject to registration under the Securities Act, that is distinguished from ordinary course trading transactions by the presence of special selling efforts and selling methods; or an offering of securities made pursuant to an effective registration statement under the Securities Act.”[22]

    The definition of “initial purchaser” is “a person who has agreed with an issuer to purchase a security from the issuer for resale to other purchasers in transactions that are not required to be registered under the Securities Act in reliance upon Rule 144A or that are otherwise not required to be registered because they do not involve any public offering.”[23]

    These definitions were not modified from the Proposed Rule.

    Sponsor

    The definition of “sponsor” under the Rule now means: (i) any person who organizes and initiates an ABS transaction by selling or transferring assets, either directly or indirectly, including through an affiliate, to the entity that issues the ABS; and (ii) any person with a contractual right to direct or cause the direction of the structure, design or assembly of an ABS or the composition of the pool of assets underlying or referenced by the ABS, other than a person who acts solely pursuant to such person’s contractual rights as a holder of a long position in the ABS; except that (A) a person that performs only administrative, legal, due diligence, custodial or ministerial acts related to the structure, design or assembly, or ongoing administration of an ABS or the composition of the pool of assets underlying or referenced by the ABS will not be a sponsor; and (B) the United States or its agency will not be a sponsor with respect to an ABS that it fully insures or fully guarantees.[24] As such, “a person who meets the definitional criteria of Rule 192(c) can be a ‘sponsor’ regardless of whether it is referred to as the ‘sponsor’ or some other title (e.g., issuer, depositor, originator or collateral manager).”[25] The definition of “sponsor” has been narrowed from the original Proposed Rule definition by excluding anyone who directs or causes the direction of the structure, design or assembly of an ABS or the composition of the pool of assets underlying the ABS.[26] It has also narrowed those who are considered sponsors due to having a “contractual right” (as noted above) by excluding a person who so acts as a holder of a long position in the ABS.

    Affiliates and Subsidiaries

    An affiliate or subsidiary qualifies as a securitization participant for purposes of the Rule only if it (i) acts in coordination with an underwriter, placement agent, initial purchaser or sponsor or (ii) has access to or receives information about the relevant ABS or the asset pool underlying or referenced by the relevant ABS prior to the date of the first closing of the sale of the relevant ABS.[27] Whether the affiliate or subsidiary acts in coordination with a securitization participant or had access to, or received, information about an ABS or its underlying asset pool or reference asset pool prior to the closing date will depend on the facts and circumstance of the transaction.[28] Among the set of particular facts and circumstances that would lead an affiliate or subsidiary of a securitization participant to not be deemed a “securitization participant” are[29]:

    • Having effective information barriers between the securitization participant and the relevant affiliate or subsidiary;
    • Maintaining separate trading accounts for the participant and the relevant affiliate or subsidiary;
    • Not having common officers or employees (other than clerical, ministerial or support personnel);
    • Engaging in unrelated businesses and not communicating with such relevant affiliated entity; or
    • If it has personnel with oversight or managerial responsibility over accounts of both the participant and affiliate or subsidiary, then such persons do not have trading (or pre-approval of trading) authority in the accounts.

    Safe Harbor

    A safe harbor has been added to the Rule such that it will not apply to any ABS which is (i) not issued by a U.S. person (as defined in 17 CFR 230.902(k)[30]) and (ii) the offer and sale of the ABS is in compliance with 17 CFR 230.901 through 905 (Regulation S)[31].

    Compliance Date

    The Rule will become effective 60 days after publication in the Federal Register. However, compliance with the Rule will be required with respect to any ABS the first closing of the sale of which occurs 18 months after the date of publication in the Federal Register.[32]

    Authored by Phillip J. Azzollini, Daniel V. Oshinsky, Craig Stein and Atul Joshi.

    If you have any questions concerning this Alert, please contact your attorney at Schulte Roth & Zabel or one of the authors.


    [1] View the text of the Rule (“Rule”).

    [2] View the SEC’s press release  (“Release”).

    [3] See Prohibition against Conflicts of Interest in Certain Securitizations, SEC Release No. 34-65355; File No. s7-38-11; (Sept. 19, 2011), 76 Fed. Reg. 60320 (Sept. 28, 2011) (“2011 Release”).

    [4] View the text of the Proposed Rule.

    [5] Rule at § 230.192(a).

    [6] Id. at § 230.192(a)(1).

    [7] Rule § 230.192(a)(3).

    [8] Release, at 103.

    [9] The term “sizeable” is an undefined term under the Release, but market participants will likely develop a consensus as familiarity with the final Rule in practice develops.

    [10] Rule at § 230.192(a)(3).

    [11] Rule at § 230.192(b).

    [12] Id. at § 230.192(b)(1).

    [13] Id. at § 230.192(b)(2).

    [14] Release, at 146.

    [15] Release, at 146.

    [16] Id. at § 230.192(b)(3).

    [17] Proposed Rule at 189.

    [18] Rule § 230.192(d).

    [19] Id. at § 230.192(c).

    [20] Release at 54-55.

    [21] Release at 34.

    [22] Id. at 34.

    [23] Id. at 35.

    [24] Rule § 230.192(c).

    [25] Id. at

    [26] Proposed Rule at 187.

    [27] Release at 69.

    [28] Id. at 75.

    [29] Id. at 76 stating that effective information barriers include “. . . written policies and procedures designed to prevent the flow of information between relevant entities, internal controls, physical separation of personnel, etc. . . .”

    [30] Rule at § 230.192(e).

    [31] Id.

    [32] Release at 170-171.


    This communication is issued by Schulte Roth & Zabel LLP for informational purposes only and does not constitute legal advice or establish an attorney-client relationship. In some jurisdictions, this publication may be considered attorney advertising. © 2023 Schulte Roth & Zabel LLP. All rights reserved. SCHULTE ROTH & ZABEL is the registered trademark of Schulte Roth & Zabel LLP.

    In depth
    Authors

    Phillip J. Azzollini

    Partner

    New York – 919 Third Avenue

    Daniel V. Oshinsky

    Partner

    New York – 919 Third Avenue

    Craig Stein

    Partner

    New York – 919 Third Avenue

    More insights

  • UK Short Selling Update: UK Reporting Threshold Goes up to 0.2 Percent From Feb. 5, 2024; Other Changes to the Short Selling Regime Anticipated

    UK Short Selling Update: UK Reporting Threshold Goes up to 0.2 Percent From Feb. 5, 2024; Other Changes to the Short Selling Regime Anticipated

    ARTICLE / CLIENT ALERT

    UK Short Selling Update: UK Reporting Threshold Goes up to 0.2 Percent From Feb. 5, 2024; Other Changes to the Short Selling Regime Anticipated

    December 14, 2023

    Read time: 5 min

    Key takeaways
    Overview

    0.2 Percent Initial Reporting Threshold for UK Shares

    The Short Selling (Notification Threshold) Regulations 2023[i] adopted as part of the post-Brexit review of the UK financial services regulatory framework will increase the initial threshold for reporting of net short positions to the UK’s Financial Conduct Authority (“FCA”) from 0.1 percent to 0.2 percent.

    The disclosure obligations apply to all holders of net short positions in companies whose shares are admitted to trading on UK trading venues. These obligations capture positions held in shares directly, on swap, or through any other financial instruments, including depository receipts, baskets and any derivatives referencing the UK-listed shares. 

    Position holders are currently reporting their net short positions to the FCA starting at 0.1 percent. This lower threshold (which replaced the original 0.2 percent threshold) was first introduced under the European Union’s Covid-19 emergency measures, but later became permanent. This has led to a significant increase in the number of reports submitted to the FCA in recent years and has created a burdensome regime for market participants with minimal additional data analysis benefit to the FCA.

    The new UK initial reporting threshold of 0.2 percent will apply from Feb. 5, 2024. From that date, position holders with net short positions below 0.2 percent will no longer be required to disclose their positions. The incremental reporting threshold of 0.1 percent for any net short positions above 0.2 percent will continue to apply.

    Under the EU Short Selling Regulation[ii], the initial threshold of 0.1 percent continues to apply to net short positions in the share capital of issuers with shares admitted to trading in EU member states.

    Other Anticipated Reforms

    The UK HM Treasury has recently published the draft Short Selling Regulations 2024[iii] (“Draft 2024 Regulations”) and its response to the consultation on further amendments to the UK short selling regime (“Consultation Response”).[iv] The following key reforms of the UK short selling regime are expected in the near term:

    • Aggregated publication of net short positions: At present, the FCA publishes the names of position holders with net short positions of 0.5 percent or more. Under the Draft 2024 Regulations, the FCA will instead publish the aggregate net short positions for each issuer (expressed as a percentage of the company’s share capital) based on the notifications it receives in respect of each business day. Individual positions and the names of position holders will no longer be disclosed publicly.
    • New powers granted to the FCA: The Draft 2024 Regulations are expected to grant the FCA rulemaking, supervisory and enforcement powers regarding short selling. As a result, the FCA will have more flexibility to make future modifications to the UK short selling regime without the need to involve the legislative process. Among other things, the FCA will have powers to make rules to exempt shares from the scope of the short selling reporting obligations. The expectation is that the FCA will, in the future, publish a “positive” list of all in-scope shares, rather than continuing with the present practice of a “negative” list of exempted shares.
    • Net short positions in UK sovereign debt and CDS: The Consultation Response confirms the UK Government’s plans to remove the current obligations on short sellers to obtain “cover” for short positions in UK sovereign debt and report net short positions of 0.5 percent or more of UK debt to the FCA. Even more significantly, the Government intends to repeal the current restrictions on buying “uncovered” sovereign CDS. Sovereign debt and sovereign credit default swaps will remain in scope of the FCA’s emergency intervention powers for short selling.

    Authored by Anna Maleva-Otto and Matthew Dow.

    If you have any questions concerning this Alert, please contact your attorney at Schulte Roth & Zabel or one of the authors.


    [i] 2023. No. 1258 The Short Selling (Notification Threshold) Regulations 2023.

    [ii] Regulation (EU) No 236/2012

    [iii] HM Treasury, The Short Selling Regulations 2024.

    [iv] HM Treasury, Short Selling Regulation Consultation – Sovereign Debt and Credit Default Swaps, 11 July 2023; and HM Treasury, Government Response to Short Selling Regulation: Consultation – Sovereign Debt and Credit Default Swaps.


    This communication is issued by Schulte Roth & Zabel LLP and Schulte Roth & Zabel International LLP for informational purposes only and does not constitute legal advice or establish an attorney-client relationship. In some jurisdictions, this publication may be considered attorney advertising. © 2023 Schulte Roth & Zabel LLP and Schulte Roth & Zabel International LLP. All rights reserved. SCHULTE ROTH & ZABEL is the registered trademark of Schulte Roth & Zabel LLP.

    In depth
    Authors
    More insights

  • New Cybersecurity, Privacy and Automated Decisionmaking Rules Coming Soon to California

    New Cybersecurity, Privacy and Automated Decisionmaking Rules Coming Soon to California

    ARTICLE / CLIENT ALERT

    New Cybersecurity, Privacy and Automated Decisionmaking Rules Coming Soon to California

    December 12, 2023

    Read time: 5 min

    Key takeaways
    Overview

    Substantial changes to the California Consumer Privacy Act (CCPA) are coming soon through five sets of proposed regulations governing (1) cybersecurity audits, (2) privacy risk assessments, (3) artificial intelligence/automated decisionmaking technology (ADMT), (4) revisions to existing regulations and (5) new rules for insurance companies. The proposed regulations are expansive and likely to be finalized in 2024, so businesses should start planning now for upcoming changes.

    In depth

    THE CPPA’S DECEMBER 8, 2023, MEETING AND CYBERSECURITY AUDIT REGULATIONS

    At its December 8 meeting, the CPPA discussed five sets of proposed CCPA regulations about:

    1. Privacy risk assessments
    2. Cybersecurity audits
    3. ADMT
    4. Changes to the existing CCPA regulations
    5. Rules for insurance companies

    The revised cybersecurity audit regulations clarify that they apply to businesses that:

    • Derived 50 percent or more of their annual revenues from selling or sharing consumers’ personal information in the preceding calendar year; or
    • As of January 1 of the calendar year, had annual gross revenues in excess of $25 million (revenue threshold to be adjusted in the other proposed rules) and in the preceding calendar year (1) processed the personal information of 250,000 or more consumers or households, (2) processed the sensitive personal information or 50,000 or more consumers or (3) processed the personal information of 50,000 or more consumers that the business had actual knowledge were less than 16 years old.

    Now that the cybersecurity audit regulations have advanced, the CPPA will publish a “statement of reasons” explaining the rules, economic and fiscal impact statements and formally issue the draft set of regulations for public comment. If past is prologue, the rulemaking process could take six to eight months or longer. However, given the scope and onerous requirements of the proposed cybersecurity audit regulations, now is the time for companies to start paying attention.

    AUTOMATED DECISIONMAKING TECHNOLOGY

    The draft regulations propose requiring businesses using ADMT in the following ways to provide pre-use notice, opt-out and access rights:

    • For a decision that produces legal or similarly significant effects on the consumer;
    • Profiling a consumer acting in their capacity as an employee, independent contractor, job applicant or student;
    • Profiling a consumer while they are in a publicly accessible place;
    • Profiling a consumer for behavioral advertising, such as evaluating consumers’ personal preferences and interests to display advertisements to them;
    • Profiling a consumer that the business has actual knowledge is under the age of 16; and
    • Processing the personal information of consumers to train ADMT.

    During the December 8 meeting, the CPPA board and staff were split on how to regulate ADMT, specifically, in the workplace. There are open questions regarding transparency for employees whose employers use ADMT in the workplace as well as potential opt-out rights for certain ADMT use cases in the employment context. The CPPA staff have been tasked with evaluating whether to (a) narrow the scope of these draft regulations or (b) develop more carve-outs from the draft rules.

    PRIVACY RISK ASSESSMENTS

    Although most of the substantive requirements remain unchanged from earlier drafts, many of the latest changes to the privacy risk assessment regulations relate to ADMT. For example, the latest proposal would require risk assessments for a broader range of ADMT, such as biometric identity detection, generation of deepfakes or the operation of generative models like large language models. Among other things, such risk assessments must cover:

    • An explanation of why the business wants to use ADMT, including the benefits of ADMT over manual processing;
    • A plain language description of the personal information processed by the ADMT;
    • A plain language explanation of the steps the business has taken or will take to maintain the quality of the personal information processed by the ADMT;
    • A description of the limitations on the ADMT use;
    • A plain language description of the logic the ADMT uses, including any assumptions made by it;
    • A plain language explanation of how the business evaluates the ADMT for validity, reliability and fairness; and
    • A description of the need for human involvement in the business’s use of the ADMT.

    CPPA board members also supported extending to 24 months the initial deadline to submit assessments to the CPPA, but they raised concerns about compliance costs and how certain provisions would survive against the injunction on California’s Age-Appropriate Design Code Act. Thus, the board members voted to send these regulations back to the staff to integrate individual board member feedback.

    CCPA REGULATION CHANGES

    The CPPA also discussed proposed changes to existing CCPA regulations, including:

    • The addition of a new Sensitive Personal Information category for information of consumers less than 16 years old;
    • The addition of more illustrative examples related to their principles of symmetry in choice and prohibition of dark patterns; and
    • Modest adjustments to the “business” revenue threshold for CCPA applicability as well as the range of financial penalties for violations of the CCPA.

    The CPPA board voted to require additional staff drafting before formal rulemaking.

    WHAT’S NEXT?

    Formal rulemaking will start in 2024, after which there will be one or more “comment periods” before the regulations can be finalized. Companies would be wise to take this opportunity to at least benchmark their current readiness against the proposed regulations and understand just how much work will be required to become compliant.

    If you have questions or need assistance with CCPA compliance or other state privacy laws, please contact any of the authors or your regular McDermott lawyer.

    Authors

    Elliot R. Golding

    Partner

    Washington, DC

    Michael G. Morgan

    Partner

    Los Angeles, Silicon Valley

    David P. Saunders

    Partner

    Chicago

    More insights

  • Requirement for Enhanced Share Repurchase Disclosures in Periodic Reports Delayed

    Requirement for Enhanced Share Repurchase Disclosures in Periodic Reports Delayed

    ARTICLE / CLIENT ALERT

    Requirement for Enhanced Share Repurchase Disclosures in Periodic Reports Delayed

    December 11, 2023

    Read time: 4 min

    Key takeaways
    Overview

    On November 22, 2023, the US Securities and Exchange Commission (SEC) issued an order postponing the effective date for the new share Repurchase Rule (88 Fed. Reg. 36002 (June 1, 2023)) pending further SEC action. The SEC’s postponement of the effective date is in response to a remand by the US Court of Appeals for the Fifth Circuit for the SEC “to correct the defects” of the Repurchase Rule. Absent the SEC’s postponement, domestic issuers with a December 31 fiscal year-end would have been required to include additional disclosures regarding their fourth quarter share repurchase activities in a new exhibit to their annual report on Form 10-K for the year ending December 31, 2023.

    The SEC’s objective in adopting the Repurchase Rule was to remedy asymmetries in information between issuers and the investing public with respect to issuers’ share repurchase activity. The Repurchase Rule as adopted by the SEC on May 3, 2023, would have expanded the reporting requirements for issuers regarding share repurchase activity by mandating the disclosure of daily repurchase data, the objectives and rationales for the repurchase program, the processes and criteria used to determine the amount of repurchases, the policies and procedures relating to purchases and sales of the issuer’s securities by its officers and directors during the period of a repurchase program, the adoption and termination of Rule 10b5-1 trading agreements, and other information. Please refer to our prior publication on the initial adoption of the Repurchase Rule for additional information regarding the disclosures required thereunder.

    The postponement of the Repurchase Rule followed an opinion issued by the Fifth Circuit in Chamber of Com. of the USA v. SEC, No. 23-60255 (5th Cir. 2023). In that case, the Court found that the SEC violated the Administrative Procedure Act in arbitrarily and capriciously adopting the rule by (i) failing to respond to comments to the Repurchase Rule and (ii) failing to conduct a proper cost-benefit analysis of the Repurchase Rule prior to its adoption.

    The Court provided the SEC with a period of 30 days expiring on November 30, 2023, to remedy procedural defects to substantiate the Repurchase Rule. On November 26, 2023, the Court denied the SEC’s request for an extension of the 30-day remedy period. On December 1, 2023, the SEC’s Office of the General Counsel submitted a letter to the Court stating that the SEC was unable to “correct the defects in the rule” within the 30-day period.

    McDERMOTT INSIGHT

    On December 7, 2023, a motion to vacate the Repurchase Rule was filed, and it is expected that the Repurchase Rule will now be vacated by the Court. The SEC may either appeal the decision or adopt a new share repurchase rule proposal that would attempt to address the defects of the previous proposal, as identified by the Court, by providing qualitative analyses of the costs and benefits of daily repurchase disclosures, substantiating the issue of informational asymmetry in the context of share repurchases and responding to comments on such new share repurchase rule prior to its adoption.

    In depth

    TEMP

    Authors

    Vlad Maly

    Partner

    London – 22 Bishopsgate

    Thomas P. Conaghan

    Partner

    Washington, DC, New York – One Vanderbilt Avenue

    Eric Orsic

    Partner

    Chicago

    Heidi J. Steele

    Partner

    Chicago

    Daniel L. Woodard

    Partner

    New York – One Vanderbilt Avenue

    More insights

  • World’s First Artificial Intelligence Regulations Established – Council and Parliament Reach Historic Accord on Pioneering Artificial Intelligence Act

    World’s First Artificial Intelligence Regulations Established – Council and Parliament Reach Historic Accord on Pioneering Artificial Intelligence Act

    ARTICLE

    World’s First Artificial Intelligence Regulations Established – Council and Parliament Reach Historic Accord on Pioneering Artificial Intelligence Act

    December 11, 2023

    Read time: 4 min

    Key takeaways
    Overview

    The European Council and the European Parliament have achieved a provisional agreement on the Artificial Intelligence (“AI”) Act, establishing the world’s first set of rules for AI. The draft regulation aims to guarantee the safety and adherence to fundamental rights and values of the European Union (“EU”) in AI systems deployed within the European market and used across the EU. This milestone proposal signals a historic achievement and clarifies the responsibilities and roles of various actors in AI development and usage.

    In depth

    Key Elements of the AI Act Provisional Agreement

    Essential elements of the provisional agreement include rules on high-impact general-purpose AI models (such as GPT-4 from OpenAI, Gemini from Google or Llama 2 from Meta), a revised governance system with EU-level enforcement powers, an expanded list of prohibitions, and enhanced protection of rights through mandatory fundamental rights impact assessments for deployers of high-risk AI systems. The agreement adopts a risk-based approach, ensuring that regulations align with the potential harm AI systems may cause. Stricter rules are set for high-impact general-purpose AI models, with severity increasing based on the perceived risk, maintaining a delicate balance between innovation promotion and risk mitigation.

    Prohibitions, Exceptions and Law Enforcement Safeguards

    The agreement outlines prohibitions on AI practices deemed too risky, including cognitive behavioural manipulation, untargeted scraping of facial images, emotion recognition in workplaces and educational institutions, social scoring, biometric categorisation etc. Exceptions are outlined for law enforcement purposes, subject to specific safeguards, including emergency procedures for urgent situations. Strict criteria are set for real-time remote biometric identification systems in publicly accessible spaces, ensuring fundamental rights protection against potential misuse.

    EU’s AI Act about to influence International Regulations

    The AI Act is positioned as a flagship legislative initiative that could establish a global standard for AI regulation, much like the General Data Protection Regulation (“GDPR”) influenced international data protection regulations. This landmark agreement is set to shape the European approach to tech regulation on the world stage. To ensure accountability, the agreement introduces fines for violations, set as a percentage of the offending company’s global annual turnover. Proportionate caps are established for Small and Medium Entrepreneurs (“SMEs”) and start-ups. Transparency measures include fundamental rights impact assessments before deploying high-risk AI systems and increased transparency in the use of such systems.

    Innovation Support: EU’s AI Regulatory Sandboxes and Measures for Small Businesses

    In support of innovation, the agreement modifies provisions to create an innovation-friendly legal framework. AI regulatory sandboxes are introduced for testing and validating innovative AI systems, allowing real-world testing. Actions are outlined to support smaller companies, with limited derogations to ease administrative burdens.

    Next steps

    The provisional agreement will undergo further technical discussions before formal adoption. The AI Act is expected to come into force two years after its entry into force, marking a significant step towards a comprehensive regulatory framework for AI in the EU.

     

    Authors

    Dr. Boris Uphoff

    Partner

    Munich, Düsseldorf

    More insights

  • Private Equity and REITs, Take Note! CMS Finalizes Nursing Facility Ownership Disclosure Requirements

    Private Equity and REITs, Take Note! CMS Finalizes Nursing Facility Ownership Disclosure Requirements

    ARTICLE / CLIENT ALERT

    Private Equity and REITs, Take Note! CMS Finalizes Nursing Facility Ownership Disclosure Requirements

    December 7, 2023

    Read time: 5 min

    Key takeaways
    Overview

    On November 17, 2023, the US Department of Health and Human Services (HHS) published a final rule requiring nursing facilities participating in Medicaid and skilled nursing facilities participating in Medicare to disclose detailed ownership, managerial, governance and personnel qualifications, with a particular focus on private equity and real estate investment trust (REIT) ownership. This data will be made public in an effort to increase transparency and provide consumers with more data to evaluate facilities and make informed choices about where to obtain nursing care.

    In depth

    NURSING FACILITY OWNERSHIP DISCLOSURE REQUIREMENTS

    Effective January 16, 2024, nursing facilities participating in Medicaid and skilled nursing facilities participating in Medicare will be required to disclose the following information when they initially submit an enrollment application via the Provider Enrollment, Chain, and Ownership System (PECOS) or a CMS-855A application (or the equivalent state enrollment form), experience a change in ownership or control, or revalidate their enrollment information:

    1. The name, title and period of service for each member of the governing body of a nursing facility
    2. The name, title and period of service for each officer, director, member, partner, trustee or managing employee of a nursing facility
    3. Each additional disclosable party of the facility
    4. The organizational structure of each additional disclosable party and a description of the relationship that the additional disclosable party has with the facility

    Changes in ownership or control of an enrolled provider, which the information above constitutes, must be reported within 30 days of the change.

    Notwithstanding the effective date of the final rule, in November, the Centers for Medicare & Medicaid Services (CMS) released an updated CMS-855A application that includes the detailed requests for ownership and managing control noted above. These revisions add private equity and REIT to the description of the types of organizations that may have an ownership interest. Skilled nursing facilities must also include a diagram of their owners. Medicare Administrative Contractors will no longer accept the prior version of the CMS-855A after December 17, 2023.

    Medicaid-enrolled nursing facilities’ ownership disclosure compliance obligations will not arise until the applicable state Medicaid agency has established the means to collect this data. CMS has instructed states to promptly establish data collection mechanisms and share the information with affected nursing facilities when available.

    NEWLY DEFINED TERMS

    Under the final rule, a “managing employee” includes a general manager, business manager, administrator, director or other individual who exercises operational or managerial control over the day-to-day operation of the facility or who directly or indirectly manages, advises or supervises any element of the practices, finances or operations of the facility. HHS specifies that this definition is intended to include a hospice or skilled nursing facility administrator or medical director.

    “Additional disclosable party” includes any person or entity who (i) exercises operational, financial or managerial control over the facility; (ii) provides policies or procedures for any of the facility’s operations; (iii) provides financial or cash management services to the facility; (iv) leases or subleases real property to the facility; (v) owns a whole or part interest equal to or exceeding 5% of the total value of the facility’s real property; (vi) provides management or administrative services; (vii) provides managerial or clinical consulting services or (viii) provides accounting or financial services to the facility.

    “Private equity” includes any publicly traded or non-publicly traded company that collects capital investments from individuals or entities and purchases a direct or indirect ownership share of a provider.

    “Real estate investment trust” is defined using the existing definition of REITs found in Section 856 of the Internal Revenue Code (IRC)—namely, a corporation, trust or association that is managed by one or more trustees or directors, with a beneficial ownership held by 100 or more persons, which ownership is evidenced by transferable shares or by transferable certificates of beneficial interest which, but for limitations in the IRC, would be taxable as a domestic corporation and is neither a financial institution nor an insurance company as defined in the IRC. This is a far narrower definition than the version in the proposed rule, which would have included any publicly traded or non-publicly traded company that owns part or all of the buildings or real estate in or on which the provider operates.

    HOW DATA WILL BE USED AND PUBLISHED

    CMS will issue further guidance regarding the timing, content and means of data publication, but it will do so through sub-regulatory guidance rather than notice and comment rulemaking. Recognizing its obligation to make the data public within one year of the final rule’s publication, CMS is deciding whether to use its Care Compare website, data.cms.gov or another venue. It is also determining how the data can be presented to allow users to understand the contents and search for trends, relationships or other connections in nursing facility ownership structures.

    IMPACT

    Applicants who fail to timely report the obligatory information or who submit inaccurate reports risk denial or revocation of their enrollment. Providers who experience a denied enrollment on this basis may be barred from reapplying for up to three years, and providers whose enrollment is revoked may be prohibited from reenrolling for up to 10 years. Providers subject to these new requirements should review them carefully and ensure that the information submitted is accurate and comprehensive.

    Authors

    Monica Wallace

    Partner

    Chicago

    More insights

  • Supreme Court Tackles Third-Party Releases in Purdue Bankruptcy – Outcome Uncertain

    Supreme Court Tackles Third-Party Releases in Purdue Bankruptcy – Outcome Uncertain

    ARTICLE / CLIENT ALERT / US POLICY

    Supreme Court Tackles Third-Party Releases in Purdue Bankruptcy – Outcome Uncertain

    December 8, 2023

    Read time: 8 min

    Key takeaways
    Overview

    Introduction

    On Dec. 4, 2023, the US Supreme Court heard oral arguments in Harrington v. Purdue Pharma L.P., No. 23-124 (US argued Dec. 4, 2023), on whether a bankruptcy court may approve a Chapter 11 reorganization plan that non-consensually releases direct claims against non-debtor third parties. The Court’s decision may dictate whether a third-party non-debtor will be able to discharge civil litigation claims without having to file for bankruptcy or follow Bankruptcy Code requirements. The Court considered extensively whether the Bankruptcy Code permits third-party releases under § 1123(b)(6) and looked at the impact of a ruling here on accepting and hold out creditors. The Court appeared divided (and not on typical ideological lines) making prediction of an outcome particularly difficult here. We expect a ruling before the end of the term in June 2024.

    Background

    Purdue Pharma, a manufacturer of branded opioid medications, including OxyContin, filed for bankruptcy on Sept. 15, 2019. The Company faced significant threats to its continued viability stemming from mass tort litigation over its marketing and sale of prescription opioid medications, including OxyContin.

    The proposed chapter 11 plan sought to resolve the opioid litigation by incorporating a settlement framework that included a release of the family that owned the equity in Purdue, the Sackler family, in exchange for a lump-sum settlement payment of $4.325 billion at the time of confirmation. The Bankruptcy Court approved this Plan and entered a confirmation order on Sept. 17, 2021. Certain parties, including the US Trustee appealed the confirmation order. On appeal (from the District Court), the Second Circuit affirmed the bankruptcy court’s confirmation of a chapter 11 reorganization plan containing nonconsensual releases of direct claims against third-party non-debtors, including the debtor’s controlling owners, the Sacklers. After a subsequent appeal by the office of the United States Trustee, the US Supreme Court granted certiorari and teed up the hearing.

    Analysis

    In a “dramatic” argument, the court questioned the parties on four main issues: the interpretation of § 1123(b)(6) in the Bankruptcy Code; the legacy a ruling may leave for future liable companies and those impacted by mass tort; the difference between direct and derivative claims; and recoveries for the mass tort plaintiffs.

    Statutory Interpretation. First, the justices tackled statutory interpretation. Justices Jackson, Kavanaugh and Gorsuch questioned the parties on the interpretation of the term “appropriate” in § 1123(b)(6) of the Bankruptcy Code. Section 1123(b)(6) states that a plan may “include any other appropriate provision not inconsistent with the applicable provisions of this title.” Arguing on behalf of the US Trustee, the Deputy Solicitor General asserted that nonconsensual third-party releases are outside the scope of the term “appropriate.” Counsel for the US Trustee argued that Congress did not intend for Bankruptcy Code § 1123(b)(6) to go beyond general principles of the Bankruptcy Code and allow bankruptcy courts to “simply redistribute others’ private property rights” without consent.

    Justice Kavanaugh asked counsel for the US Trustee to explain his position in light of decades of cases where claims against directors were indemnified by the debtor and therefore properly incorporated into the plan of reorganization. Counsel for the US Trustee argued that “[t]his [Plan] really sweeps much more broadly than that. It isn’t just people who are directors and officers.”

    In contrast, counsel to Purdue emphasized flexibility, arguing that “‘[a]ppropriate’ is a term of classic breadth. It essentially gives the courts a common law role that while broad is part and parcel of what bankruptcy courts and equity courts have been doing for centuries in this context.”

    Justice Jackson, however, questioned counsel to Purdue on how the statutory context informs his interpretation of § 1123(b)(6), asking why in this case should the Court depart from its standard interpretation of statutory lists. Counsel to Purdue argued that §§ 1123(b)(1)-(5) work directly with § 1123(b)(6) in that each provision grants the authority needed by the bankruptcy court for a plan to be effective. Section 1123(b)(6) is the catch-all provision that encapsulates what is not specifically mentioned in §§ 1123(b)(1)-(5). Justice Gorsuch observed that counsel to Purdue’s position lacked the support of a strong historical analogue. Not only was this issue the most significant point of questioning from the Court but also will likely be a deciding factor in the Court’s opinion.

    Impact on Future Mass Torts. Second, the Justices focused on how this case might impact future mass tort bankruptcies, with Justice Barrett inquiring into potential ramifications for victims in cases such as LTL Management.[1] To resolve issues related to mass torts, counsel for the US Trustee suggested that Congress could step in “as it did with § 524(g) of the Bankruptcy Code which permits the resolution of mass torts related to asbestos litigation, and create a customized framework for some of these individual case[s].” Counsel to Purdue countered that should the Debtors’ position not be validated, the Court would have to find § 524(g) unconstitutional, taking a “wrecking ball” to the asbestos bankruptcy carve-out and the rest of the Code.

    Direct and Derivative Claims. Third, the justices spent considerable time questioning the parties about direct versus derivative claims. Both parties agreed that similar to direct claims, derivative claims belong to individual creditors under state law. However, upon filing for bankruptcy, the estate secures the exclusive right to litigate or settle such claims for the benefit of all creditors. Justice Sotomayor questioned counsel to Purdue on this distinction, noting that she did not understand why the personal injury claims were not derivative claims given that the defective product was sold by the corporation not the Sackler parties. Counsel to Purdue responded that, in this case, the direct claims were “functionally indistinguishable from the derivative claims,” thereby making them dischargeable without consent under § 1123(b)(6), On rebuttal, counsel for the US Trustee argued that the derivative claims are ones that can be recovered from “… the corporation as a whole,” and that, in this case, the mass tort plaintiffs’ claims were direct, not derivative. Specifically with respect to the state government claims against the estate, counsel to the UCC explained the importance of the release, stating that if the release is eliminated each of the states’ claims will be resurrected because they are direct claims.

    Making Creditors Whole. Lastly, Justices Kavanaugh and Barrett asked the parties the best way to make mass tort victims whole once more. According to Justice Kagan, the trustee’s position, and the position of the hold out creditors could be “standing in the way of [recovery] as against the huge, huge, huge majority of claimants who have decided that, if this provision goes under, they’re going to end up with nothing.” Counsel to Purdue suggested this as well, pointing out repeatedly that the Plan has the support of 97 percent of the voting plaintiffs. Counsel for the US Trustee responded that even in a situation where there was the hypothetical “nut-case holdout” who did not consent to the Plan, that holdout creditor should still have its day in court and should not be forced to relinquish its property rights in its claim as a non-debtor third party. Justice Jackson also pointed out that even if there are holdouts, the Sackler parties could still fund victims who do consent and litigate with any holdouts. Counsel to the UCC argued that the US Government’s $2 billion super-priority claim against the Sacklers, if not discharged through the Plan, would flatten the estate, leaving little to nothing for the plaintiffs to collect.

    Conclusion

    As detailed above, the Court focused foremost on § 1123(b)(6) of the Bankruptcy Code and whether third-party releases are “appropriate” provisions to include in a plan. This, as well as the ideologically mixed nature of the arguments, suggests that any ruling here will focus narrowly on the propriety of the releases of direct claims at issue in this case – rather than a broader ruling on whether and when third-party releases are permitted broadly. The Plan proponents here faced heavy questioning on the propriety of these releases from the Court. However, the Court also placed some emphasis on the practical impact of this ruling. And the Court may be reluctant to undermine a plan with widespread consent and recovery for creditors.

    Authored by Douglas S. Mintz, Reuben E. Dizengoff, and Christiana Johnson.

    If you have any questions concerning this Alert, please contact your attorney or one of the authors.

    In depth
    Authors

    Reuben E. Dizengoff

    Partner

    New York – 919 Third Avenue

    More insights

  • Chicago Employees to Receive 10 Days of Paid Leave

    Chicago Employees to Receive 10 Days of Paid Leave

    ARTICLE / CLIENT ALERT

    Chicago Employees to Receive 10 Days of Paid Leave

    December 5, 2023

    Read time: 5 min

    Key takeaways
    Overview

    As of December 31, 2023, all employees physically working in Chicago for at least two hours in a two-week period will earn both one hour of paid leave and one hour of paid sick leave for every 35 hours worked, pursuant to an ordinance passed by the Chicago City Council on November 9, 2023. The new ordinance expands the current ordinance, which requires employers to provide only paid sick leave to employees.

    In depth

    CHANGES TO PAID LEAVE IN THE WINDY CITY

    The new ordinance expands the eligibility requirements and will now include all employers who gainfully employ at least one employee performing at least two hours of work while physically present within the geographic boundaries of the city of Chicago in any two-week period. Notably, the employer need not be located in Chicago for the new ordinance to apply.

    And the changes do not stop there. Unlike the existing ordinance, employees will now receive 10 paid leave days divided into two categories: five days of general paid leave and five days of paid sick leave. Employers may choose to provide the leave as an accrual method (“earn as you go”) or decide to frontload each type of leave on the first day of each 12-month accrual period. While both types of leave will accrue at a rate of one hour for every 35 hours worked, the two categories have their nuances:

    Paid Leave Days Paid Sick Leave
    When do employees become eligible to use the leave? Employees become eligible to use paid leave after 90 days of employment. Employees become eligible to take paid sick leave after 30 days of employment.
    Are employees required to seek approval or provide notice of the leave? Employers can require pre-approval to use paid leave, but employees are allowed to use their leave for any reason. Employers may not require an employee to provide documentation of the leave reason. Employees may be required to provide up to seven days’ notice to use paid sick time or as soon as the employee becomes aware they will need to use paid sick time. Employers can request documentation from a doctor if employees use three or more consecutive days of paid sick leave.
    What can leave be used for? Employees may use paid leave for any reason. Paid sick leave can be used to recover from illness, care for a family member, address domestic violence or in response to public health emergencies.
    How much leave can be taken at one time? Paid leave must be used in four-hour increments. Paid sick leave may be taken in two-hour increments.
    Does leave carry over from one year to the next? Employees may be entitled to carry over up to two days (16 hours) of paid leave, unless the paid leave is frontloaded. Employees will be allowed to carry over up to 10 days (80 hours) of sick time, regardless of whether paid sick leave is accrued or frontloaded.

    PAYOUT OF PAID LEAVE UPON SEPARATION AND TRANSFER

    The new ordinance includes various levels of payout of paid leave, determinative of the employer’s workforce:

    • Employers with 100 or more Chicago employees will be required to pay out any unused, accrued paid time off.
    • Employers with 51 to 100 Chicago employees will be required to pay out a maximum of two days (16 hours) of accrued, unused paid leave until December 31, 2024, unless the employer has set a higher limit. On January 1, 2025, these employers will be required to pay out all unused, accrued paid leave.
    • Employers with less than 50 employees are not required to pay out any unused, accrued paid leave.

    Remarkably, the new ordinance requires payout of paid leave (if any) upon both separation of employment and if the employee transfers outside of the geographic boundaries of Chicago. Regardless of the size of the workforce, employers are not required to pay out accrued but unused paid sick leave upon separation or transfer out of Chicago.

    NOTICE REQUIREMENTS

    The new ordinance requires that employers provide employees with notice of paid leave policies, including:

    • Providing written notice to employees of paid time off policies when they receive their first paycheck and annually with a paycheck issued within 30 days of July 1 of every year.
    • Providing notice within five days before any changes to the employer’s policies.
    • Posting a physical notice advising employees of their right to paid time off in a conspicuous place at each physical location where any employee works in Chicago.

    EMPLOYER CONSIDERATIONS

    Employers looking to avoid penalties (which can range between $1,000 and $3,000 for each separate offense, not including notice failures) should ensure their policies are in compliance, taking care to ensure employees are accruing one hour of paid leave and paid sick leave for every 35 hours worked. Additionally, employers should make sure any requirements imposed on taking and using leave are reasonable under the new ordinance. Note that unlimited paid time off policies are compliant with the new ordinance.

    Importantly, the Illinois Paid Leave for All Workers Act (PLAWA), which takes effect on January 1, 2024, will not apply to the Chicago Ordinance, as the PLAWA excludes “any employer that is covered by a municipal or county ordinance…that requires employers to give any form of paid leave to their employees, including paid sick leave or paid leave.” Nonetheless, employers with employees in Illinois, in Chicago and beyond should take care to ensure their policies are compliant with this seemingly ever-changing area of the law in the Land of Lincoln.

    Authors

    Melis Solaksubasi

    Associate

    Chicago

    Brian Mead

    Partner

    Chicago

    More insights

  • HHS Promotes Improved Accessibility To Department-Funded Activities for Individuals With Limited English Proficiency

    HHS Promotes Improved Accessibility To Department-Funded Activities for Individuals With Limited English Proficiency

    ARTICLE / CLIENT ALERT

    HHS Promotes Improved Accessibility To Department-Funded Activities for Individuals With Limited English Proficiency

    December 5, 2023

    Read time: 10 min

    Key takeaways
    Overview

    On November 15, 2023, the US Department of Health and Human Services (HHS) released its updated Language Access Plan (Updated Plan) to further ensure that the limited English proficiency (LEP) community and individuals with disabilities can meaningfully access HHS-administered and -funded programs and activities. The Updated Plan establishes practical guidance, best practices and action steps for HHS agencies to develop their own agency-specific access plans.

    In depth

    Appropriate communication is integral to ensuring that individuals can access healthcare and human services programs to which they are entitled. However, nearly 10% of the US population over age five has limited English proficiency (LEP), and many of these individuals are unaware of governmental assistance programs or how to access them. Data coming out of the COVID-19 pandemic has shown that inequitable access to programs and services offered by HHS exacerbated already disproportionate negative health outcomes. Recognizing this inequity and appreciating its obligation to avoid discrimination on the basis of (among other things) race, color, national origin and disability under Title VI of the Civil Rights Act of 1964 and Section 1557 of the Affordable Care Act (Section 1557) as well as various executive orders, HHS issued its Updated Plan on November 15, 2023.

    The Updated Plan aims to ensure HHS and HHS agencies continue to provide access for individuals with disabilities and LEP to programs and activities administered and funded by HHS. The Updated Plan revises direction promulgated by HHS in 2013 and sets forth practical guidance, best practices and action steps for HHS agencies to develop agency-specific language access plans, outlining 10 essential elements that each HHS agency’s language access plan should address. Each element identifies specific steps and timelines that HHS agencies must follow in implementing HHS’s language access policy at the agency level.

    HHS AGENCIES COVERED UNDER THE UPDATED PLAN

    The Updated Plan applies to all agencies across HHS, including the Centers for Medicare and Medicaid Services, the Food and Drug Administration, the Health Resources and Services Administration, the Indian Health Service, the National Institutes of Health, and the Office for Civil Rights.

    SPECIFIC COMPONENTS OF THE UPDATED PLAN

    Under the Updated Plan, HHS describes 10 essential elements necessary to improve access to programs and activities funded by HHS or administered by HHS agencies for persons with LEP. Many of the recommendations strive to address service weaknesses, changes in technology, and priorities of the Biden administration coming out of the COVID-19 pandemic. For example, the Updated Plan includes steps to provide: (1) webpages in languages other than English, (2) telephonic and video or virtual interpreting services, (3) program and benefit information in languages other than English and (4) federal funding for language assistance services.

    The 10 essential elements outlined in the Updated Plan and the material policies and action steps associated with each element are highlighted and summarized as follows:

    Element 1: Assessment: Needs and Capacity

    • Every March, assess the language assistance needs of the agency’s current and potential customers to inform policy, processes and budgeting necessary to increase awareness of and implement language assistance services that increase access to the agency’s programs, activities and services for persons with LEP.
    • Consider the needs of non-English speakers, including those communicating with sign language, as part of the assessment.
    • Determine the resources necessary to identify those who need language assistance and barriers that impact individuals with LEP from experiencing effective interpretation and written communication.
    • Include in HHS agencies’ action plans mechanisms for hiring qualified multilingual staff, ensuring the availability of independent contractor translators and interpreters, and developing or amending policies to ensure language assistance services are appropriate for the applicable agency’s customers.

    Element 2: Interpretation Language Assistance Services

    • Provide, free of charge, appropriate interpretation language assistance services (g., face-to-face, virtual and/or telephone encounters) through qualified bilingual and multilingual staff, and through qualified interpreters.
    • Provide appropriate auxiliary aids and services, such as qualified sign language interpreters, on-site or through video remote interpreting services to people with disabilities.
    • Designate an office or official responsible for establishing agency-wide procedures for providing interpreting services within 180 days of issuance of the Updated Plan.
    • Establish over-the-phone and video remote interpreting help lines that will quickly connect callers who speak the 15 most commonly spoken languages in the relevant state(s) to telephonic or video interpreters.

    Element 3: Written Translations

    • Provide accurate written translations to ensure meaningful access to and an equal opportunity to receive timely public health and social services information and participate fully in the services, activities, programs or other benefits administered by the agency.
    • Develop translated documents using plain language, cultural communication and health literacy, as appropriate, to make the materials more easily understandable.
    • Refrain from using machine translation or other artificial intelligence applications to convert written text from one language to another without the involvement of a qualified human translator.
    • Ensure vital documents are provided in the preferred languages for the LEP communities served, and produce materials in other languages when requested or otherwise appropriate.
    • Offer translated written materials, particularly vital documents, in non-written formats, including audio, video with subtitles, video with sign language, and infographics, for persons with limited literacy or disabilities, and for those whose language does not have a written form.
    • Provide customers with a notice of nondiscrimination and availability of free language assistance and appropriate auxiliary services, consistent with requirements under Section 1557 of the ACA.

    Element 4: Policies, Procedures, and Practices

    • Establish and maintain an infrastructure designed to implement and improve language assistance services within the agency.
    • Collect and share metrics to monitor implementation and efficacy of agency plans.
    • Ensure policies, procedures and all language assistance activities are developed and implemented in alignment with the National Standards for Culturally and Linguistically Appropriate Services in Health and Health Care.
    • Develop policies and procedures for receiving and addressing language assistance concerns or complaints from customers with LEP and customers with disabilities who require auxiliary aids or services for effective communication.

    Element 5: Notification of the Availability of Language Assistance at No Cost

    • Distribute resources such as HHS LEP guidance directly and online to all current recipients, providers, contractors and vendors.
    • Use various methods and networks, including public service announcements, non-English media, and community- and faith-based resources, to ensure that LEP communities are informed that language assistance is available from the agency.
    • Develop and prominently display appropriate language taglines on vital documents, web pages currently available only in English or in a limited number of non-English languages, technical assistance and outreach materials, and other documents notifying the availability of language assistance at no cost.
    • Use the assessment from Element 1 as guidance regarding the languages in which notifications and vital documents should be translated.

    Element 6: Staff Training

    • Establish a process that ensures overall employee awareness of the agency’s language assistance plan.
    • Create a dedicated internal resource webpage that can serve as a repository of standard operating procedures, guidance documents, training opportunities and other materials necessary to support staff capacity, capability and competence.

    Element 7: Assessment and Accountability: Access, Quality, Resources, Reporting

    • Implement an agency process to annually report to HHS’s Language Access Steering Committee on agency progress implementing each element of the Updated Plan.
    • Implement methods for measuring improvements in language access in individual programs and activities and for ensuring that such information is collected in a manner that increases comparability, accuracy and consistency across different agencies’ programs and activities.
    • Address complaints received regarding language assistance services and products, or other services provided by the agency, in a timely manner, retaining a record of any resolution of such complaints, and making resolutions and agreements available to public.

    Element 8: Consultation with Health Care and Human Services Partners

    • Plan and coordinate conversations with healthcare and human services partners, including agency program beneficiaries, to assess the accessibility, accuracy, cultural appropriateness and overall quality of the agency’s language assistance services.
    • Share language access plans and resources with healthcare and human services partners, solicit feedback and incorporate stakeholder input into language access plans.
    • Host at least one annual listening session (e.g., town hall, conference call) to learn about challenges and opportunities for improvement in the agency’s language access program.
    • Post agency language access plans and resources on agency websites in accessible formats and in multiple languages, along with a way for stakeholders to provide questions and comments, and share relevant data and information pertaining to language access with healthcare and human services partners.

    Element 9: Digital Information

    • Ensure digital information is appropriate, available and accessible to people with LEP in languages other than English.
    • Prominently display links and/or symbols at the top-right corner of the agency’s English-language website redirecting users to pages and documents that are also available for viewing or downloading in languages other than English, including sign language.
    • Display links on the agency’s English-language homepage redirecting users to effective, multilingual telephonic interpreter services.
    • Ensure that any virtual meeting platform being used provides for closed captioning and that the captioning function is enabled by the host.
    • Leverage social media, email dissemination and/or text message services to increase awareness and utilization of HHS agency programs, activities, language assistance services and products available in non-English languages by individuals with LEP and people with disabilities.
    • Evaluate practicability of using real-time translation services to ensure better accuracy of captions.
    • Ensure that virtual meeting participants are able to highlight another participant’s screen and keep focus on that screen so that sign language users can focus on a sign language interpreter.
    • In meeting invitations, provide an option for virtual attendees to request auxiliary aids and services or reasonable modifications to facilitate participation by individuals with disabilities.

    Element 10: Grant Assurance and Compliance by Recipients of HHS Funding

    • Develop and incorporate LEP requirements or best practices in funding opportunity announcements (e.g., requiring HHS grant applicants to submit language access procedures or policies with their applications).
    • Ensure civil rights compliance language and guidance is included in each grant-making agency’s program outreach materials to the extent feasible, including ensuring compliance by the recipient’s program staff, sub-recipients and contractors.

    TIMELINE FOR DEVELOPING AND IMPLEMENTING AGENCY-SPECIFIC LANGUAGE ACCESS PLANS

    Within six months of the issuance of the Updated Plan, HHS agencies must develop and implement agency-specific language access plans and policies that incorporate and identify action steps to implement all 10 elements of the Updated Plan. HHS agencies must also obtain input from the healthcare and human services partners.

    While the Updated Plan is primarily intended to promote meaningful access to HHS agencies’ programs and activities for individuals with LEP, HHS has noted that many aspects of the Updated Plan also will help ensure that HHS agencies are communicating effectively with persons with disabilities, including persons who rely on sign language to communicate in compliance with Section 504 of the Rehabilitation Act of 1973. As covered entities prepare for release of the Section 1557 final rule, the Updated Plan likely serves as a foreshadowing of what is to come and provides guideposts on how parties can implement compliance plans.

    Authors
    More insights

  • Illinois Supreme Court: Finger-Scan Information Collected by Healthcare Providers to Access Medications Is Exempt From BIPA Liability

    Illinois Supreme Court: Finger-Scan Information Collected by Healthcare Providers to Access Medications Is Exempt From BIPA Liability

    ARTICLE / CLIENT ALERT

    Illinois Supreme Court: Finger-Scan Information Collected by Healthcare Providers to Access Medications Is Exempt From BIPA Liability

    December 4, 2023

    Read time: 5 min

    Key takeaways
    Overview

    On November 30, 2023, the Illinois Supreme Court unanimously held in Mosby et al. v. The Ingalls Memorial Hospital et al. that when biometrics of healthcare employees are collected in the course of providing medical services, that biometric collection is exempt from the Illinois Biometric Information Privacy Act (BIPA).

    In depth

    The plaintiff, Lucille Mosby, was a registered nurse employed by UChicago Medicine Ingalls Memorial Hospital. She alleged that she used a medication dispensing system that required her to scan her finger on a device in order to access the medication. Another plaintiff in the case, Yana Mazya, was a registered nurse at Northwestern Medicine Lake Forest Hospital. Mazya, along with Tiki Taylor, a patient care technician, sued the hospital. They alleged that the healthcare providers required scans of fingerprints for identification to access medication dispensing systems and to gain authorized access to stored materials and medications for patients.

    The defendants argued that Section 10 of BIPA exempted this collection from the scope of BIPA. Specifically, section 10 provides that biometric identifiers’ “information collected, used, or stored for health care treatment, payment, or operations under” the Health Insurance Portability and Accountability Act of 1996 (HIPAA) is exempt from BIPA. In its opinion, the court honed in on whether this exclusion “includes a health care worker’s biometric information used to access patient medications and provide patient care.” The court answered that narrow question in the affirmative, holding that the exclusion does apply to collection and use of a healthcare worker’s biometric information to access patient medications and to provide patient care.

    In its analysis, the court reasoned that the phrase “under HIPAA” in the statutory text made “clear that the legislature was directing readers to HIPAA to discern the meaning of those terms.” The terms “treatment, payment, [and] operations” are defined terms under HIPAA. Healthcare includes “care, services, or supplies related to the health of an individual,” including the “sale or dispensing of a drug, device, equipment, or other item in accordance with a prescription.” Treatment means the “provision, coordination, or management of health care and related services by one or more health care providers,” including “the coordination or management of health care by a health care provider with a third party; consultation between health care providers relating to a patient; or the referral of a patient for health care from one health care provider to another.” The term “payment” includes “activities undertaken by *** [a] health care provider or health plan to obtain or provide reimbursement for the provision of health care.” Finally, “health care operations” means, in part, “the following activities of the covered entity to the extent that the activities are related to covered functions”: conducting quality assessment and improvement activities, including, among other things, patient safety activities and protocol development; reviewing the competence or qualifications of healthcare professionals; and conducting or arranging for medical review and auditing functions, including fraud and abuse detection and compliance programs.

    Reviewing these defined terms in HIPAA, the court explained:

    Therefore, the legislature’s decision to use the phrase “health care treatment, payment, and operations” and to immediately follow it with the prepositional phrase “under [HIPAA]” makes clear that the legislature was directing readers to HIPAA to discern the meaning of those terms. HIPAA’s definitions of these terms relate to activities performed by the health care provider—not by the patient.

    The court ultimately held that BIPA “excludes from its protections the biometric information of health care workers where that information is collected, used, or stored for health care treatment, payment, or operations as those functions are defined by HIPAA. A health care worker’s biometric information, used to permit access to medication dispensing stations for patient care, falls under ‘information collected, used, or stored for health care treatment, payment, or operations under [HIPAA]’ and is exempt from the Act’s protections pursuant to section 10 of the Act.” See 740 ILCS 14/10

    This holding by the court is the first major victory for the defense bar in BIPA cases before the court. Practitioners, however, should be wary of attempts to expand this holding to argue that it creates a categorical exclusion of biometric identifiers taken from healthcare workers. Indeed, the court cautioned that it was not creating a “broad, categorical exclusion of biometric identifiers taken form health care workers.”

    For assistance in establishing or evaluating existing BIPA policies, contact your regular McDermott lawyer or the authors.

    Authors

    Daniel Campbell

    Partner

    Chicago

    David P. Saunders

    Partner

    Chicago

    More insights